Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Employees - 4,
CEO - Dr. Tiago Reis Marques M.D., Ph.D.,
Sector - Healthcare,
Country - US,
Market Cap - 3.73M
Altman ZScore(max is 10): -5.04, Piotroski Score(max is 10): 1, Working Capital: $6248444, Total Assets: $16064719, Retained Earnings: $-49582778, EBIT: -14249962, Total Liabilities: $1282043, Revenue: $0
- Current Price $1.38 - Analyst Target Price $40.00| Ticker | KTTA |
| Index | - |
| Curent Price | 1.38 |
| Change | 0.73% |
| Market Cap | 3.73M |
| Average Volume | 2.78M |
| Income | -13.90M |
| Sales | 0.00M |
| Book Value/Share | 10.60 |
| Cash/Share | 2.56 |
| Dividend Est | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Employees | 4 |
| Moving Avg 20days | 6.94% |
| Moving Avg 50days | 7.18% |
| Moving Avg 200days | -58.17% |
| Shares Outstanding | 2.71M |
| Earnings Date | - |
| Inst. Ownership | 2.85% |
| Price/Earnings | - |
| Forwad P/E | - |
| PE Growth | - |
| Price/Sales | - |
| Price/Book | 0.13 |
| Price/Cash | 0.54 |
| Price/FCF | - |
| Quick Ratio | 6.58 |
| Current Ratio | 6.58 |
| Debt/Equity | 0.00 |
| Return on Assets | -65.93% |
| Return on Equity | -72.83% |
| Return on Investment | -94.06% |
| Gross Margin | - |
| Ops Margin | - |
| Profit Margin | - |
| RSI | 52.78 |
| BETA(β) | 0.49 |
| From 52week Low | 49.58% |
| From 52week High | -82.05% |
| EPS | -12.69 |
| EPS next Year | - |
| EPS next Qtr | - |
| EPS this Year | - |
| EPS next 5 Year | - |
| EPS past 5 Year | -282.28% |
| Sales past 5 Year | -25.00% |
| EPS Y/Y | 4.70% |
| Sales Y/Y | -100.00% |
| EPS Q/Q | 50.40% |
| Sales Q/Q | - |
| Sales Surprise | -33.33% |
| EPS Surprise | -5.88% |
| ATR(14) | 0.22 |
| Perf Week | -13.75% |
| Perf Month | 20.00% |
| Perf Quarter | -43.67% |
| Perf Year | -83.76% |
| Perf YTD | -56.19% |
| Target Price | 40.00 |
AryaFin Engine© - An AI FinTech Venture - 2024-25 Disclaimer